Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Investor Place · 06/09 11:26
Inside Kineta's plans after unveiling reverse merger deal
Kineta, a Seattle-based biotech, announced plans to go public through a reverse merger with Boston-based Yumanity. The deal could offer Kineta a major boost for its drug development pipeline.
American City Business Journals · 06/08 21:43
Yumanity Therapeutics to sell its pipeline, merge with Seattle biotech
The long-embattled neurodegenerative disease company will cease to exist after the deals are complete.
American City Business Journals · 06/07 17:48
Short Volatility Alert: Yumanity Therapeutics, Inc.
On Monday, shares of Yumanity Therapeutics, Inc. (NASDAQ: YMTX) experienced volatile short activity. After the activity, the stock price went up +40.14% to $1.99.  The overall sentiment for YMTX has been Bearish.
Benzinga · 06/07 15:37
Mirati, CymaBay top healthcare gainers; Verastem, Delcath lead losers' pack
Gainers: Mirati Therapeutics (MRTX) +23%. CymaBay Therapeutics (CBAY) +16%. Veru (VERU) +9%. Kodiak Sciences (KOD) +8%. Allarity Therapeutics (ALLR) +7%. Losers: Verastem (VSTM) -12%. Delcath Systems (DCTH) -11%. Vicarious Surgical (RBOT) -8%. CEL-SCI (CVM...
Seekingalpha · 06/07 14:04
Mid-Afternoon Market Update: Dow Turns Lower; DiDi Global Shares Surge
U.S. stocks pared gains, with the Dow Jones turning lower toward the end of trading on Monday.
Benzinga · 06/06 18:42
VIEW, UONE and STRY among mid-day movers
Gainers: Aero Clean Technologies (AERC) +58%. DiDi Global (DIDI) +39%. Yumanity Therapeutics (YMTX) +31%. Pineapple Energy (PEGY) +25%. View (VIEW) +26%. ATIF Holdings (ATIF) +26%. The Arena Group Holdings (AREN)
Seekingalpha · 06/06 16:53
Mid-Day Market Update: Nasdaq Rises 1%; Praxis Precision Medicines Shares Plunge
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 1% on Monday.
Benzinga · 06/06 16:36
52 Stocks Moving In Monday's Mid-Day Session
Gainers DiDi Global Inc. (NYSE: DIDI) jumped 51.4% to $2.80 after the Chinese government said the company can resume adding new users.
Benzinga · 06/06 16:11
WWDC 2022: 11 Things to Know About This Year’s Apple Developers Event
Investor Place · 06/06 14:40
Benzinga's Premarket Brief On Trending Tickers: Amazon, Alibaba, DiDi, Solaredge, And More
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.
Benzinga · 06/06 14:14
Yumanity, Babylon top healthcare gainers; while Praxis, eFFECTOR lead losers' pack
Gainers:  Yumanity Therapeutics YMTX +46%. Babylon (BBLN) +11%. Sema4 (SMFR) +11%. Nano-X Imaging (NNOX) +10%. Satsuma Pharmaceuticals (STSA) +10%. Losers: Praxis Precision Medicines PRAX -63%. eFFECTOR Therapeutics (EFTR) -20%. Pear Therapeutics (PEAR) -1...
Seekingalpha · 06/06 14:05
Why Is Yumanity Therapeutics (YMTX) Stock Up 50% Today?
Investor Place · 06/06 14:04
Yumanity Therapeutics Shares Trading Higher Today - Read Here Why
Benzinga · 06/06 12:37
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 06/06 12:34
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Investor Place · 06/06 11:29
Yumanity stock soars 46% on all-stock merger with Kineta; lead product sale to J&J for $26M
Yumanity Therapeutics (NASDAQ:YMTX) is selling its lead clinical-stage product YTX-7739 to Johnson & Johnson (NYSE:JNJ) for $26M in cash and is merging with privately-held Kineta in an all-stock transaction. Yumanity said it is selling
Seekingalpha · 06/06 11:21
Yumanity to Merge With Kineta; Sells Drug Candidate to Janssen Unit for $26 Million; Shares Jump
MT Newswires · 06/06 11:18
BRIEF-Yumanity Therapeutics To Merge With Kineta In All-Stock Deal · 06/06 10:49
Yumanity Therapeutics Announces Definitive Agreements For Two Strategic Transactions
Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV in a $26 million cash
Benzinga · 06/06 10:31
Webull provides a variety of real-time YMTX stock news. You can receive the latest news about Yumanity Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About YMTX
Yumanity Therapeutics Inc., formerly Proteostasis Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. The Company's technology platform enables the rapid screening for novel disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks. The Company's product candidate, YTX-7739, is in Phase I clinical trials for the treatment and disease modification of Parkinson's disease and YTX-9184, in IND-enabling studies for the treatment of dementia with Lewy bodies. The Company's pipeline consists of additional programs for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's Disease) and frontotemporal lobar degeneration (FTLD) is undergoing research through Merck.